Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Conmed, Lowers Price Target to $123

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $127 to $123.

byBenzinga Newsdesk

August 2, 2022

1 minute read

Needham analyst Mike Matson maintains Conmed (NYSE:CNMD) with a Buy and lowers the price target from $127 to $123.

SNDL Enhances Its Cannabis Retail Operations Via Conclusion Of Superette Group’s CCAA Proceedings

By Vuk Zdinjak

Today, 5:27 AM

SNDL Inc. (NASDAQ: SNDL) announced that, in the context of the Superette Group's proceedings under the Companies' Creditors Arrangement Act (Canada) (the "CCAA"), it has successfully closed the transaction contemplated by the agreement of purchase

SNDL

Benzinga’s Top Ratings Upgrades, Downgrades For June 30, 2021

By Benzinga Insights

Today, 5:27 AM

Upgrades

AJX

Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A

By Vandana Singh

Today, 5:27 AM

According to Roche Holding AG's (OTC: RHHBY) Genentech division, new data from a phase 3b study reinforces the safety profile of blockbuster hemophilia A treatment Hemlibra.

RHHBF

William Blair Initiates Coverage On Sprinklr with Outperform Rating

By Benzinga Newsdesk

Today, 5:27 AM

William Blair analyst Arjun Bhatia initiates coverage on Sprinklr (NYSE:CXM) with a Outperform rating.

CXM

Needham Maintains Buy on Conmed, Lowers Price Target to $123

Related Posts

SNDL Enhances Its Cannabis Retail Operations Via Conclusion Of Superette Group’s CCAA Proceedings

Benzinga’s Top Ratings Upgrades, Downgrades For June 30, 2021

Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A

William Blair Initiates Coverage On Sprinklr with Outperform Rating